UCSF Collaboration

December 17, 2019

Prof. Hideho Okada at the University of California San Francisco is collaborating with ImmunoScape on a study to evaluate the vaccine-specific T cell response induced by a rationally designed vaccine administered to a targeted group of patients with WHO grade II glioma, a form of brain cancer that often progresses into an aggressive high-grade glioma, such as glioblastoma. 

Prof. Okada states “I’m excited to be working with ImmunoScape on this pivotal study. Their platform enables a very comprehensive analysis of CD8 T cells, a key immune cell induced by the vaccine administered to these patients. The monitoring and assessment of these cells in patients might shed some light on their importance in treatment outcomes and drive future vaccine design for this fatal disease with unmet clinical needs.”